Literature DB >> 2884116

Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension.

G Frithz, L Weiner.   

Abstract

Fifty patients with essential hypertension WHO Grades I-II have been treated for 3 months with bisoprolol, a new selective beta blocker, in doses up to 40 mg once daily. Forty-three patients reached the preset target diastolic blood pressure of less than or equal to 90 mmHg on a mean daily dose of 16.8 mg bisoprolol. There was no effect on serum lipids and HDL-cholesterol during the study. The side-effects were mild and were those usually associated with beta-blocking therapy.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2884116     DOI： 10.1007/bf00609961

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  13 in total

Review 1.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applications.

Authors:  W Frishman; R Silverman
Journal:  Am Heart J       Date:  1979-07       Impact factor: 4.749

2.  Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.

Authors:  R C Tarazi; H P Dustan
Journal:  Am J Cardiol       Date:  1972-05       Impact factor: 2.778

3.  The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1984-05

4.  Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis.

Authors:  P Dorow; U Tönnesmann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Drugs and the heart. VII. Which drug for which disease?

Authors:  L H Opie
Journal:  Lancet       Date:  1980-05-10       Impact factor: 79.321

6.  Serum triglycerides, to be or not to be a risk factor for ischaemic heart disease?

Authors:  L A Carlson; L E Böttiger
Journal:  Atherosclerosis       Date:  1981-06       Impact factor: 5.162

7.  Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups.

Authors:  L Weiner; G Frithz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

9.  Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.

Authors:  H J Schliep; J Harting
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

10.  Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects.

Authors:  S Rössner; L Weiner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953
View more
  2 in total

Review 1.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

2.  Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study.

Authors:  V Channaraya; R K Marya; M Somasundaram; Debashish Mitra; K D Tibrewala
Journal:  BMJ Open       Date:  2012-05-14       Impact factor: 2.692
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.